{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,3]],"date-time":"2026-11-03T04:49:36Z","timestamp":1793681376812,"version":"4.5.1"},"reference-count":31,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2025,4,1]],"date-time":"2025-04-01T00:00:00Z","timestamp":1743465600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,4,1]],"date-time":"2025-04-01T00:00:00Z","timestamp":1743465600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,2,21]],"date-time":"2025-02-21T00:00:00Z","timestamp":1740096000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100013057","name":"Heffter Research Institute","doi-asserted-by":"publisher","award":["HYIFA-2022-01"],"award-info":[{"award-number":["HYIFA-2022-01"]}],"id":[{"id":"10.13039\/100013057","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001711","name":"Swiss National Science Foundation","doi-asserted-by":"publisher","award":["01EW1908"],"award-info":[{"award-number":["01EW1908"]}],"id":[{"id":"10.13039\/501100001711","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","thelancet.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["eClinicalMedicine"],"published-print":{"date-parts":[[2025,4]]},"DOI":"10.1016\/j.eclinm.2025.103149","type":"journal-article","created":{"date-parts":[[2025,3,14]],"date-time":"2025-03-14T14:37:24Z","timestamp":1741963044000},"page":"103149","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":63,"special_numbering":"C","title":["Psilocybin-assisted therapy for relapse prevention in alcohol use disorder: a phase 2 randomized clinical trial"],"prefix":"10.1016","volume":"82","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-5804-1409","authenticated-orcid":false,"given":"Nathalie M.","family":"Rieser","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Raoul","family":"Bitar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Simon","family":"Halm","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christina","family":"Rossgoderer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ladina P.","family":"Gubser","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maeva","family":"Th\u00e9venaz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yara","family":"Kreis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Robin","family":"von Rotz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carlos","family":"Nordt","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Monika","family":"Visentini","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Flora","family":"Moujaes","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Etna J.E.","family":"Engeli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andres","family":"Ort","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Erich","family":"Seifritz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9053-6164","authenticated-orcid":false,"given":"Franz X.","family":"Vollenweider","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marcus","family":"Herdener","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Katrin H.","family":"Preller","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.eclinm.2025.103149_bib1","doi-asserted-by":"crossref","first-page":"1923","DOI":"10.1016\/S0140-6736(18)32225-6","volume":"392","author":"Stanaway","year":"2018","journal-title":"Lancet"},{"key":"10.1016\/j.eclinm.2025.103149_bib2","doi-asserted-by":"crossref","first-page":"2","DOI":"10.35946\/arcr.v40.3.02","article-title":"Epidemiology of recovery from alcohol use disorder","volume":"40","author":"Tucker","year":"2020","journal-title":"Alcohol Res"},{"key":"10.1016\/j.eclinm.2025.103149_bib3","first-page":"356","article-title":"Treating alcoholism as a chronic disease: approaches to long-term continuing Care","volume":"33","author":"McKay","year":"2011","journal-title":"Alcohol Res Health"},{"key":"10.1016\/j.eclinm.2025.103149_bib4","doi-asserted-by":"crossref","first-page":"296","DOI":"10.1080\/08964289.2020.1760777","article-title":"Effects of multiple detoxifications on withdrawal symptoms, psychiatric distress and alcohol-craving in patients with an alcohol use disorder","volume":"47","author":"Ooms","year":"2021","journal-title":"Behav Med"},{"key":"10.1016\/j.eclinm.2025.103149_bib5","first-page":"348","article-title":"Alcohol dependence, withdrawal, and relapse","volume":"31","author":"Becker","year":"2008","journal-title":"Alcohol Res Health"},{"key":"10.1016\/j.eclinm.2025.103149_bib6","doi-asserted-by":"crossref","first-page":"579","DOI":"10.1007\/164_2017_79","article-title":"Advances in pharmacotherapy development: human clinical studies","volume":"248","author":"Litten","year":"2018","journal-title":"Handb Exp Pharmacol"},{"key":"10.1016\/j.eclinm.2025.103149_bib7","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1111\/acer.13267","article-title":"Psychiatric, demographic, and brain morphological predictors of relapse after treatment for an alcohol use disorder","volume":"41","author":"Durazzo","year":"2017","journal-title":"Alcohol Clin Exp Res"},{"key":"10.1016\/j.eclinm.2025.103149_bib8","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1016\/j.jsat.2008.04.001","article-title":"A\u00a0quantitative review of the ubiquitous relapse curve","volume":"36","author":"Kirshenbaum","year":"2009","journal-title":"J\u00a0Subst Abuse Treat"},{"key":"10.1016\/j.eclinm.2025.103149_bib9","doi-asserted-by":"crossref","first-page":"1434","DOI":"10.1177\/0269881110382466","article-title":"Acute, subacute and long-term subjective effects of psilocybin in healthy humans: a pooled analysis of experimental studies","volume":"25","author":"Studerus","year":"2011","journal-title":"J\u00a0Psychopharmacol"},{"key":"10.1016\/j.eclinm.2025.103149_bib10","doi-asserted-by":"crossref","first-page":"544","DOI":"10.1016\/j.biopsych.2014.11.015","article-title":"Acute effects of lysergic acid diethylamide in healthy subjects","volume":"78","author":"Schmid","year":"2015","journal-title":"Biol Psychiatry"},{"key":"10.1016\/j.eclinm.2025.103149_bib11","doi-asserted-by":"crossref","first-page":"994","DOI":"10.1177\/0269881112439253","article-title":"Lysergic acid diethylamide (LSD) for alcoholism: meta-analysis of randomized controlled trials","volume":"26","author":"Krebs","year":"2012","journal-title":"J\u00a0Psychopharmacol"},{"key":"10.1016\/j.eclinm.2025.103149_bib12","doi-asserted-by":"crossref","first-page":"289","DOI":"10.1177\/0269881114565144","article-title":"Psilocybin-assisted treatment for alcohol dependence: a proof-of-concept study","volume":"29","author":"Bogenschutz","year":"2015","journal-title":"J\u00a0Psychopharmacol"},{"issue":"10","key":"10.1016\/j.eclinm.2025.103149_bib13","doi-asserted-by":"crossref","first-page":"953","DOI":"10.1001\/jamapsychiatry.2022.2096","article-title":"Percentage of heavy drinking days following psilocybin-assisted psychotherapy vs placebo in the treatment of adult patients with alcohol use disorder: a randomized clinical trial","volume":"79","author":"Bogenschutz","year":"2022","journal-title":"JAMA Psychiatry"},{"key":"10.1016\/j.eclinm.2025.103149_bib14","doi-asserted-by":"crossref","first-page":"187","DOI":"10.1007\/7854_2021_284","article-title":"Psychedelic-assisted therapy for substance use disorders and potential mechanisms of action","volume":"56","author":"Rieser","year":"2022","journal-title":"Curr Top Behav Neurosci"},{"key":"10.1016\/j.eclinm.2025.103149_bib15","article-title":"Single-dose psilocybin-assisted therapy in major depressive disorder: a placebo-controlled, double-blind, randomised clinical trial","volume":"56","author":"Rotz","year":"2023","journal-title":"EClinicalMedicine"},{"key":"10.1016\/j.eclinm.2025.103149_bib16","doi-asserted-by":"crossref","first-page":"1402","DOI":"10.1056\/NEJMoa2032994","article-title":"Trial of psilocybin versus escitalopram for depression","volume":"384","author":"Carhart-Harris","year":"2021","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.eclinm.2025.103149_bib17","doi-asserted-by":"crossref","first-page":"619","DOI":"10.1016\/S2215-0366(16)30065-7","article-title":"Psilocybin with psychological support for treatment-resistant depression: an open-label feasibility study","volume":"3","author":"Carhart-Harris","year":"2016","journal-title":"Lancet Psychiatry"},{"key":"10.1016\/j.eclinm.2025.103149_bib18","doi-asserted-by":"crossref","first-page":"843","DOI":"10.1001\/jama.2023.14530","article-title":"Single-dose psilocybin treatment for major depressive disorder: a randomized clinical trial","volume":"330","author":"Raison","year":"2023","journal-title":"JAMA"},{"key":"10.1016\/j.eclinm.2025.103149_bib19","doi-asserted-by":"crossref","first-page":"1181","DOI":"10.1177\/0269881116675513","article-title":"Psilocybin produces substantial and sustained decreases in depression and anxiety\u00a0in patients with life-threatening cancer: a randomized double-blind trial","volume":"30","author":"Griffiths","year":"2016","journal-title":"J\u00a0Psychopharmacol"},{"key":"10.1016\/j.eclinm.2025.103149_bib20","doi-asserted-by":"crossref","first-page":"80","DOI":"10.1097\/00131746-200603000-00003","article-title":"The BRENDA model: integrating psychosocial treatment and pharmacotherapy for the treatment of alcohol use disorders","volume":"12","author":"Starosta","year":"2006","journal-title":"J\u00a0Psychiatr Pract"},{"key":"10.1016\/j.eclinm.2025.103149_bib21","series-title":"Aclohol timeline followback users\u2019 manual","author":"Sobell","year":"1995"},{"key":"10.1016\/j.eclinm.2025.103149_bib22","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0012412","article-title":"Psychometric evaluation of the altered states of consciousness rating scale (OAV)","volume":"5","author":"Studerus","year":"2010","journal-title":"PLoS One"},{"key":"10.1016\/j.eclinm.2025.103149_bib23","doi-asserted-by":"crossref","first-page":"577","DOI":"10.15288\/qjsa.1959.20.577","article-title":"Use of d -lysergic acid diethylamide in the treatment of alcoholism","volume":"20","author":"Chwelos","year":"1959","journal-title":"Q\u00a0J Stud Alcohol"},{"key":"10.1016\/j.eclinm.2025.103149_bib24","doi-asserted-by":"crossref","first-page":"392","DOI":"10.1038\/s41398-023-02690-1","article-title":"Psilocybin-induced default mode network hypoconnectivity is blunted in alcohol-dependent rats","volume":"13","author":"Reinwald","year":"2023","journal-title":"Transl Psychiatry"},{"key":"10.1016\/j.eclinm.2025.103149_bib25","doi-asserted-by":"crossref","first-page":"994","DOI":"10.3389\/fphar.2018.00994","article-title":"LSD administered as a single dose reduces alcohol consumption in C57BL\/6J mice","volume":"9","author":"Alper","year":"2018","journal-title":"Front Pharmacol"},{"key":"10.1016\/j.eclinm.2025.103149_bib26","doi-asserted-by":"crossref","first-page":"1316","DOI":"10.1038\/s41386-020-0694-z","article-title":"Psilocybin and LSD have no long-lasting effects in an animal model of alcohol relapse","volume":"45","author":"Meinhardt","year":"2020","journal-title":"Neuropsychopharmacology"},{"key":"10.1016\/j.eclinm.2025.103149_bib27","doi-asserted-by":"crossref","first-page":"1068","DOI":"10.1016\/S2215-0366(19)30222-6","article-title":"Psychiatric comorbidities in alcohol use disorder","volume":"6","author":"Castillo-Carniglia","year":"2019","journal-title":"Lancet Psychiatry"},{"key":"10.1016\/j.eclinm.2025.103149_bib28","doi-asserted-by":"crossref","first-page":"1637","DOI":"10.1056\/NEJMoa2206443","article-title":"Single-dose psilocybin for a treatment-resistant episode of major depression","volume":"387","author":"Goodwin","year":"2022","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.eclinm.2025.103149_bib29","doi-asserted-by":"crossref","first-page":"1165","DOI":"10.1177\/0269881116675512","article-title":"Rapid and sustained symptom reduction following psilocybin treatment for anxiety and depression in patients with life-threatening cancer: a randomized controlled trial","volume":"30","author":"Ross","year":"2016","journal-title":"J\u00a0Psychopharmacol"},{"key":"10.1016\/j.eclinm.2025.103149_bib30","doi-asserted-by":"crossref","first-page":"496","DOI":"10.1080\/15622975.2022.2151043","article-title":"The efficacy of neurofeedback for alcohol use disorders - a systematic review","volume":"24","author":"Dave","year":"2023","journal-title":"World J Biol Psychiatr"},{"key":"10.1016\/j.eclinm.2025.103149_bib31","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.addbeh.2018.01.036","article-title":"Applications of virtual reality in individuals with alcohol misuse: a systematic review","volume":"81","author":"Ghi\u0163\u0103","year":"2018","journal-title":"Addict Behav"}],"container-title":["eClinicalMedicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2589537025000811?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2589537025000811?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,8,7]],"date-time":"2026-08-07T20:42:59Z","timestamp":1786135379000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2589537025000811"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,4]]},"references-count":31,"alternative-id":["S2589537025000811"],"URL":"https:\/\/doi.org\/10.1016\/j.eclinm.2025.103149","relation":{},"ISSN":["2589-5370"],"issn-type":[{"value":"2589-5370","type":"print"}],"subject":[],"published":{"date-parts":[[2025,4]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Psilocybin-assisted therapy for relapse prevention in alcohol use disorder: a phase 2 randomized clinical trial","name":"articletitle","label":"Article Title"},{"value":"eClinicalMedicine","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.eclinm.2025.103149","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 The Author(s). Published by Elsevier Ltd.","name":"copyright","label":"Copyright"}],"article-number":"103149"}}